Page 84 - Read Online

Page 352 Jones et al. J Transl Genet Genom 2021;5:341-56 https://dx.doi.org/10.20517/jtgg.2021.19

resistance PCa, targeting these epigenetic changes that facilitate AR target gene activation has a highly
possible and promising potential in developing novel therapeutic approaches. Though whether targeting
these factors’ stability will produce toxic or ineffective effects is obscure, pre-clinical trial data gathered and
documented by our lab indicates that clinical trial participation could result in highly efficient and optional
treatment methods.

DECLARATIONS
Authors’ contributions
Made substantial contributions to conception, material articulation, and editing of the review: Jones K
Provided administrative, technical, and material support: Zhang Y
Provided material support: Kong Y, Wang R, Farah E, Li C, Wang X, Zhang Z, Wang J, Mao F
Contributed to the conception and design of the review: Liu X, Liu J

Availability of data and materials
Not applicable.

Financial support and sponsorship
The work was supported by NIH grants R01 CA157429 (Liu X), R01 CA192894 (Liu X), R01 CA196835
(Liu X), and R01 CA196634 (Liu X). The work was also supported by the DTCB internal fellowship (Liu J).

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70:7-30. DOI PubMed
2. Juárez Soto A, Caballero Cobos R, Campanario Pérez R, et al. [Abiraterone in castration resistant prostate cancer]. Arch Esp Urol
2018;71:651-63. PubMed
3. Kong Y, Zhang Y, Mao F, et al. Inhibition of EZH2 Enhances the antitumor efficacy of metformin in prostate cancer. Mol Cancer
Ther 2020;19:2490-501. DOI PubMed PMC
4. Zhang Z, Cheng L, Li J, et al. Inhibition of the Wnt/β-Catenin pathway overcomes resistance to enzalutamide in castration-resistant
prostate cancer. Cancer Res 2018;78:3147-62. DOI PubMed PMC
5. Chen X, Liu J, Cheng L, et al. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant
prostate cancer. Prostate 2020;80:256-66. DOI PubMed
6. Kong Y, Cheng L, Mao F, et al. Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant
prostate cancer (CRPC). J Biol Chem 2018;293:14328-41. DOI PubMed PMC
7. Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med
2014;371:1028-38. DOI PubMed PMC
8. Wang R, Sun Y, Li L, et al. Preclinical study using malat1 small interfering RNA or androgen receptor splicing variant 7 degradation
®
enhancer ASC-J9 to suppress enzalutamide-resistant prostate cancer progression. Eur Urol 2017;72:835-44. DOI PubMed PMC
9. Yamamoto Y, Loriot Y, Beraldi E, et al. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice
variants suppress enzalutamide-resistant prostate cancer cell growth. Clin Cancer Res 2015;21:1675-87. DOI PubMed
10. Farah E, Li C, Cheng L, et al. NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer
cells. J Biol Chem 2019;294:8543-54. DOI PubMed PMC
11. Biswas S, Rao CM. Epigenetic tools (the writers, the readers and the erasers) and their implications in cancer therapy. Eur J